Caplyta in Borderline Personality Disorder
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 60 people enrolled
- Started
- 10 May 2023
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Caplyta
- Placebo
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Men and women age 18-65
- Primary diagnosis of BPD
- Zanarini scale score of at least 9 at baseline
- Currently receiving for at least the last 2 months prior to study entry some form of weekly cognitive behavioral therapy
- Ability to understand and sign the consent form
Who cannot take part
- Use of any new psychotropic medication started within the last 3 months prior to study initiation
- Previous treatment with Caplyta
- Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
- Subjects with schizophrenia or bipolar I disorder
- Subjects with an active substance use disorder
- Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
- Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
- Subjects considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
- Illegal substance use based on urine toxicology screening (excluding marijuana given the high rates of marijuana use in BPD and the lack of interaction with Caplyta)
Where in United States
- University of Chicago Medical CenterChicago, United States
About the trial
What the trial wants to find out
The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies).
The 2 groups in the trial
- PlaceboPlacebo, for comparison
All subjects who are randomized to Placebo will receive an identical placebo pill to the experimental drug starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. After study conclusion (week 8), the dose will be discontinued.
- CaplytaTreatment being tested
All subjects who are randomized to Caplyta will receive 42mg/day starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. Dosage changes and reductions will not be permitted. After study conclusion (week 8), the dose will be discontinued.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double-Blind, Placebo-Controlled Study of Caplyta in the Treatment of Borderline Personality Disorder
- Record updated
- 29 July 2026